{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:15:46Z","timestamp":1794266146612,"version":"4.9.0"},"reference-count":102,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Improved supportive care, more precise risk stratification, and personalized chemotherapy based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to near 90%. Further increase in cure rate can be expected from the discovery of additional recurrent molecular lesions, coupled with the development of novel targeted treatment through high-throughput genomics and innovative drug-screening systems. We discuss specific areas of research that promise to further refine current treatment and to improve the cure rate and quality of life of the patients.<\/jats:p>","DOI":"10.1182\/blood-2012-05-378943","type":"journal-article","created":{"date-parts":[[2012,6,23]],"date-time":"2012-06-23T04:21:08Z","timestamp":1340425268000},"page":"1165-1174","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":419,"title":["Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?"],"prefix":"10.1182","volume":"120","author":[{"given":"Ching-Hon","family":"Pui","sequence":"first","affiliation":[{"name":"Departments of Oncology and"},{"name":"Pathology, St Jude Children's Research Hospital, Memphis, TN;"},{"name":"University of Tennessee Health Science Center, Memphis, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[{"name":"Pathology, St Jude Children's Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Evans","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, TN; and"},{"name":"Department of Pharmaceutical Science, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, TN; and"},{"name":"Department of Pharmaceutical Science, St Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111808284601500_B1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2009.250","article-title":"Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.","volume":"24","author":"Conter","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111808284601500_B2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.","volume":"24","author":"M\u00f6ricke","year":"2010","journal-title":"Leukemia"},{"issue":"14","key":"2019111808284601500_B3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia from 1990-2005: a report from the Children's Oncology Group.","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111808284601500_B4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111808284601500_B5","first-page":"136","article-title":"Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: results from DFCI-ALL Consortium Protocol 00\u201301 [abstract].","volume":"114","author":"Vrooman","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111808284601500_B6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/leu.2009.251","article-title":"Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.","volume":"24","author":"Schmiegelow","year":"2010","journal-title":"Leukemia"},{"issue":"26","key":"2019111808284601500_B7","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation.","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808284601500_B8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2009.256","article-title":"Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.","volume":"24","author":"Mitchell","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2019111808284601500_B9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update.","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808284601500_B10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.2287","article-title":"The Pediatric Cancer Genome Project.","volume":"44","author":"Downing","year":"2012","journal-title":"Nat Genet"},{"issue":"9617","key":"2019111808284601500_B11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia.","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"2019111808284601500_B12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.genom.3.032802.115046","article-title":"Genetics of myeloid leukemias.","volume":"3","author":"Kelly","year":"2002","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"2","key":"2019111808284601500_B13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7380","key":"2019111808284601500_B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"5","key":"2019111808284601500_B15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403673","article-title":"High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative.","volume":"19","author":"Sutcliffe","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"2019111808284601500_B16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","article-title":"Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.","volume":"110","author":"Nachman","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111808284601500_B17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial.","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"issue":"31","key":"2019111808284601500_B18","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group Study.","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111808284601500_B19","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2009.42","article-title":"Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)\/TCF3-PBX1.","volume":"23","author":"Jeha","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2019111808284601500_B20","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2005-12-011809","article-title":"Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.","volume":"108","author":"Matloub","year":"2006","journal-title":"Blood"},{"issue":"13","key":"2019111808284601500_B21","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111808284601500_B22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"26","key":"2019111808284601500_B23","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"26","key":"2019111808284601500_B24","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1182\/blood-2009-11-256131","article-title":"Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.","volume":"115","author":"Cario","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111808284601500_B25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2010-07-297135","article-title":"Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.","volume":"117","author":"Ensor","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111808284601500_B26","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","article-title":"Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study.","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111808284601500_B27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808284601500_B28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111808284601500_B29","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"2019111808284601500_B30","article-title":"Novel genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.","author":"Roberts","journal-title":"Cancer Cell"},{"issue":"7137","key":"2019111808284601500_B31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"issue":"7191","key":"2019111808284601500_B32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2019111808284601500_B33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/sj.leu.2404691","article-title":"High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.","volume":"21","author":"Kuiper","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"2019111808284601500_B34","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","article-title":"Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).","volume":"114","author":"Iacobucci","year":"2009","journal-title":"Blood"},{"issue":"31","key":"2019111808284601500_B35","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.","volume":"27","author":"Martinelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808284601500_B36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/leu.2010.87","article-title":"IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.","volume":"24","author":"Kuiper","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"2019111808284601500_B37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ng.432","article-title":"Germline genomic variants associated with childhood acute lymphoblastic leukemia.","volume":"41","author":"Trevi\u00f1o","year":"2009","journal-title":"Nat Genet"},{"issue":"9","key":"2019111808284601500_B38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.430","article-title":"Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.","volume":"41","author":"Papaemmanuil","year":"2009","journal-title":"Nat Genet"},{"issue":"23","key":"2019111808284601500_B39","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia.","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9648","key":"2019111808284601500_B40","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"2019111808284601500_B41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","article-title":"Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.","volume":"144","author":"Gaikwad","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808284601500_B42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","article-title":"A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia.","volume":"113","author":"Kearney","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111808284601500_B43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111808284601500_B44","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2. A report from the iBFM Study Group.","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"7337","key":"2019111808284601500_B45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia.","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"issue":"7337","key":"2019111808284601500_B46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma.","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"23","key":"2019111808284601500_B47","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","article-title":"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.","volume":"29","author":"Hof","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808284601500_B48","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","article-title":"Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111808284601500_B49","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood-2011-10-382861","article-title":"Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.","volume":"119","author":"Kang","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111808284601500_B50","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2011.34.7427","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia.","volume":"29","author":"Inaba","year":"2011","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111808284601500_B51","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.","volume":"114","author":"Stumpel","year":"2009","journal-title":"Blood"},{"issue":"23","key":"2019111808284601500_B52","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","article-title":"Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.","volume":"115","author":"Schafer","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111808284601500_B53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","article-title":"Improved prognosis for older adolescents with acute lymphoblastic leukemia.","volume":"29","author":"Pui","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111808284601500_B54","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.2011.40.8617","article-title":"Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007.","volume":"30","author":"Pui","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808284601500_B55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng.763","article-title":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.","volume":"43","author":"Yang","year":"2011","journal-title":"Nat Genet"},{"key":"2019111808284601500_B56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2011.227","article-title":"ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.","volume":"26","author":"Bhojwani","year":"2012","journal-title":"Leukemia"},{"issue":"15","key":"2019111808284601500_B57","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcome after remission induction failure in childhood acute lymphoblastic leukemia.","volume":"366","author":"Schrappe","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111808284601500_B58","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111808284601500_B59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1993.11.3.527","article-title":"Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial.","volume":"11","author":"Tubergen","year":"1993","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808284601500_B60","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/sj.leu.2401974","article-title":"Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92.","volume":"14","author":"Harms","year":"2000","journal-title":"Leukemia"},{"issue":"8","key":"2019111808284601500_B61","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","article-title":"Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.","volume":"88","author":"Hurwitz","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"2019111808284601500_B62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2141.2011.08846.x","article-title":"Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.","volume":"155","author":"Maloney","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808284601500_B63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2006-01-0066","article-title":"A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.","volume":"108","author":"Coustan-Smith","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111808284601500_B64","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2011-09-381731","article-title":"Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.","volume":"119","author":"Kawedia","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111808284601500_B65","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukemia.","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111808284601500_B66","first-page":"9","article-title":"Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (trial AIEOP-BFM ALL 2000) [abstract].","volume":"112","author":"Schrappe","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111808284601500_B67","doi-asserted-by":"crossref","first-page":"586s","DOI":"10.1200\/jco.2011.29.15_suppl.9504","article-title":"Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group Study AALL0232 [abstract].","volume":"29","author":"Winick","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808284601500_B68","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1200\/JCO.2007.13.8404","article-title":"Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.","volume":"26","author":"Yang","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111808284601500_B69","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1200\/JCO.2010.32.5340","article-title":"Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.","volume":"29","author":"Mikkelsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808284601500_B70","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111808284601500_B71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2010-12-322909","article-title":"Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.","volume":"118","author":"Matloub","year":"2011","journal-title":"Blood"},{"key":"2019111808284601500_B72","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.18_suppl.3","article-title":"Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX\/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group Study AALL0232 [abstract].","volume":"29","author":"Larsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808284601500_B73","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia.","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808284601500_B74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2009.262","article-title":"Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.","volume":"24","author":"Gaynon","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111808284601500_B75","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/leu.2009.253","article-title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).","volume":"24","author":"Silverman","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2019111808284601500_B76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"2019111808284601500_B77","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia [published online ahead of print April 9, 2012].","author":"Liu","journal-title":"Leukemia"},{"issue":"22","key":"2019111808284601500_B78","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/blood-2011-07-367904","article-title":"Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.","volume":"118","author":"Willer","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111808284601500_B79","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-ASE therapy in acute lymphoblastic leukemia patients.","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"2019111808284601500_B80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111808284601500_B81","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808284601500_B82","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2141.2011.08971.x","article-title":"Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?","volume":"157","author":"Tokimasa","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111808284601500_B83","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"2019111808284601500_B84","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","article-title":"Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.","volume":"91","author":"Relling","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2019111808284601500_B85","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1182\/blood-2008-11-187880","article-title":"Methotrexate\/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.","volume":"113","author":"Schmiegelow","year":"2009","journal-title":"Blood"},{"issue":"9544","key":"2019111808284601500_B86","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(06)69558-5","article-title":"Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.","volume":"14:368","author":"Vora","year":"2006","journal-title":"Lancet"},{"issue":"14","key":"2019111808284601500_B87","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2009-07-230656","article-title":"Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.","volume":"115","author":"Stork","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111808284601500_B88","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clpt.2006.07.002","article-title":"The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.","volume":"80","author":"Lennard","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"2019111808284601500_B89","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Non-adherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a Report from the Children's Oncology Group.","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808284601500_B90","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MOP.0b013e32833fde85","article-title":"Pharmacogenomics in pediatric leukemia.","volume":"22","author":"Paugh","year":"2010","journal-title":"Curr Opin Pediatr"},{"issue":"7","key":"2019111808284601500_B91","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa035091","article-title":"Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.","volume":"349","author":"Pui","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111808284601500_B92","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2009.22.5060","article-title":"Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.","volume":"28","author":"Goldsby","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808284601500_B93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","article-title":"Current management and challenges of malignant disease in the CNS in paediatric leukaemia.","volume":"9","author":"Pui","year":"2008","journal-title":"Lancet Oncol"},{"key":"2019111808284601500_B94","article-title":"Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukaemia [published online ahead of print June 12, 2012].","author":"Richards","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2019111808284601500_B95","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood"},{"issue":"18","key":"2019111808284601500_B96","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2007.12.4149","article-title":"Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia.","volume":"26","author":"Jansen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111808284601500_B97","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2008-12-186502","article-title":"A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.","volume":"114","author":"Kadan-Lottick","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111808284601500_B98","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/pbc.23060","article-title":"Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.","volume":"57","author":"Mrakotsky","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2019111808284601500_B99","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cncr.26337","article-title":"Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses.","volume":"118","author":"Ness","year":"2012","journal-title":"Cancer"},{"key":"2019111808284601500_B100","article-title":"Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.","author":"Conklin","journal-title":"J Natl Cancer Inst"},{"key":"2019111808284601500_B101","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ng.585","article-title":"Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.","volume":"42","author":"Sherborne","year":"2010","journal-title":"Nat Genet"},{"issue":"7","key":"2019111808284601500_B102","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2011.38.0345","article-title":"ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.","volume":"30","author":"Xu","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/6\/1165\/1362335\/zh803212001165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/6\/1165\/1362335\/zh803212001165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:51:57Z","timestamp":1574085117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/6\/1165\/30512\/Pediatric-acute-lymphoblastic-leukemia-where-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,9]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,8,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-05-378943","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,9]]}}}